Abstract:e20530 Background: MET exon 14 skipping ( METex14) is characterized oncogenic that possesses susceptibility to targeted inhibitors. We retrospectively investigated a Chinese Pan-cancer cohort to characterize METex14 alterations and co-mutation. Methods: We screened tumor tissues or body fluids of a pan-cancer patients by DNA-based next-generation sequencing assay (Genetron Health) from 2017 to 2020. And distribution of co-mutation with METex14 was analyzed. Results: 233 samples from 187 patients (190 tissues and 43 circulating tumor DNA) were identified with METex14. Average age of these METex14 patients was 67.84 ± 12.19 years old, indicating they were characterized by advanced age. The cancer distribution involved METex14 was 95.72% of lung cancer (179 cases), 3.21% of brain tumors (4 glioma blastoma, 1 anaplastic astrocytoma and 1 ependymoma), 0.535% of gastrointestinal stromal tumor (1 case) and 0.535% of sarcoma (1 case). Referring to different transcripts (NM_001127500.1/2 or NM_000245.2), a total of 68 distinct sequence variants of METex14 were identified spanning functional regions: 31 forms in splice donor site (SD, 148 cases, including 1 case of D1010H), 5 in splice acceptor site (SA, 5 cases), 13 in poly-pyrimidine tract (PPT, 15 cases), 19 cover PPT and SA (19 cases). In non-lung cancers, 5 of 8 cases were detected of METex14 variation in SD site. Among the driver coexisting cases of lung cancer, METex14 samples mainly coexisted with MET amplification, EGFR driver mutations and functional fusions. Co-mutation cases with MET amplification (13) and SEMA3D-MET fusion (1) may benefit from MET inhibitors, which may be the same as the samples of METex14 alone. 13 of METex14 cases occurred with MDM2 and 9 of CDK4 amplification, respectively. There were 2 of METex14 cases coexisted with EGFR 19del or L858R, which may benefit from combination or sequential therapies of MET inhibitor and EGFR TKIs. In addition, 2 of METex14 cases were detected with functional fusions (1 ALK-EML4, 1 KIFI5B-RET), resulting in potential benefit from combination of corresponding targeted agents. Among non-lung cancer cases, 2 of 8 case had coexistence of METex14 and MET amplification, 6 of 8 patients had coexistence of METex14 and TP53, similar phenomenon was also observed in lung cancer samples. Conclusions: Here we reported diverse METex14 alterations in a Chinese pan-cancer cohort that contribute to oncogenic transformation. METex14 mutations of pan-cancer mainly occurred in SD site. TP53 was its main co-mutant gene among pan-cancers, and MET amplification was also observed.

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers

Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib

Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

The Characteristics of MET Exon 14 Skipping Mutations in Chinese Non-Small Cell Lung Cancer: A Retrospective Analysis.

Investigation on the Prognostic Impact of Concurrent Genomic Alterations in Crizotinib-Treated EML4-ALK-rearranged Advanced Non-Small Cell Lung Cancer Patients.

Comprehensive analysis of <i>MET</i> mutations in NSCLC patients in a real-world setting

Characterization of MET exon 14 skipping in pancancer.

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation and Amplification in 5,008 Patients With Lung Cancer

A Pooled Analysis of Clinical Outcome in Driver-Gene Negative Non-Small Cell Lung Cancer Patients with MET Overexpression Treated with Gumarontinib

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib Versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Crizotinib in Advanced Non-Small-cell Lung Cancer with Concomitant ALK Rearrangement and C-Met Overexpression

MA05.07 Intertumoral Molecular Heterogeneity of Non-small Cell Lung Cancer with MET Exon 14 Skipping

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer

Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data

Phase 3 Study of First-Line Crizotinib Vs Pemetrexed−cisplatin/carboplatin (PCC) in East Asian Patients (pts) with ALK+ Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance

Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study

Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic Colorectal Cancer